

Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claim 1 (Currently Amended) A method of treating a critically ill patient or a critically ill polyneuropathy (CIPNP)-patient having a blood glucose level of greater than 130 mg/dL, said method comprising administering insulin, an insulin analogue, an active derivative of insulin or an insulin analogue, or a physiologically acceptable salt of said derivative to said critically ill patient or said CIPNP-patient in an amount effective to ~~maintain~~ reduce blood glucose levels in said patient to within a range of from about 60 mg/dL to about 130 mg/dL.

Claims 2-3 (Cancelled)

Claim 4 (Previously Presented) A method of treating a patient suffering from CIPNP, said method comprising treating said patient with insulin, an insulin analogue, an active derivative of insulin or an insulin analogue, or a physiologically acceptable salt of said derivative in an amount effective to treat said CIPNP.

Claims 5-6 (Cancelled)

Claim 7 (Previously Presented) The method of claim 4, wherein the insulin, insulin analogue, active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative is administered in an amount effective to maintain blood glucose levels in said patient within a range of from about 60 mg/dL to about 130 mg/dL.

Claim 8 (Previously presented) The method of claim 7, wherein said blood glucose levels are

maintained within a range of from about 80 mg/dL to about 110 mg/dL.

Claim 9 (Previously presented) The method of claim 4, wherein said blood glucose levels are maintained for 8 hours or more.

Claim 10 (Previously presented) The method of claim 9, wherein said blood glucose levels are maintained for 24 hours or more.

Claim 11 (Previously presented) The method of claim 10, wherein said blood glucose levels are maintained for 4 days or more.

Claim 12 (Previously presented) The method of claim 4, wherein the patient is a mammal.

Claim 13 (Previously Presented) The method of claim 12, wherein the patient is a human.

Claim 14 (Previously Presented) The method of claim 13, wherein the patient is non-diabetic.

Claims 15-21 (Cancelled)

Claim 22 (Currently Amended) The method of claim 1, wherein said insulin, an insulin analogue, an active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative is administered to said critically ill patient or to said CIPNP patient in an amount effective to ~~maintain~~ reduce blood glucose levels in said patient to within a range from about 70 mg/dL to about 120 mg/dL.

Claim 23 (Currently Amended) The method of claim 1, wherein said insulin, an insulin analogue, an active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative is administered to said critically ill patient or to said CIPNP patient in an amount effective to ~~maintain~~ reduce blood glucose levels in said patient to within a range from

about 80 mg/dL to about 110 mg/dL.

Claim 24 (Previously presented) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 8 hours or more.

Claim 25 (Previously presented) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 24 hours or more.

Claim 26 (Previously presented) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 4 days or more.

Claim 27 (Previously presented) The method of claim 1, wherein the patient is a mammal.

Claim 28 (Previously presented) The method of claim 27, wherein the patient is a human.

Claim 29 (Previously presented) The method of claim 28, wherein the patient is non-diabetic.

Claims 30-31 (Cancelled)

Claim 32 (Previously Presented) The method of claim 1, wherein an insulin analogue is administered to said critically ill patient or CIPNP patient.

Claim 33 (Previously Presented) The method of claim 32, wherein said insulin analogue is Asp^{B28} human insulin.

Claim 34 (Previously Presented) The method of claim 32, wherein said insulin analogue is Lys^{B28}, Pro^{B29} human insulin.

Claim 35 (Previously Presented) The method of claim 1, wherein an active derivative of an

insulin analogue or a physiologically acceptable salt of said derivative is administered to said critically ill patient or CIPNP patient.

Claim 36 (Previously Presented) The method of claim 35, wherein said active derivative of an insulin analogue is des-Thr^{B30} human insulin γ Lys^{B29} tetradecanoyl.

Claim 37 (Previously Presented) The method of claim 1, wherein insulin is administered to said critically ill patient or CIPNP patient.

Claim 38 (Previously Presented) The method of claim 37, wherein said insulin is human insulin.

Claim 39 (Previously Presented) The method of claim 1, wherein said insulin, insulin analogue, active derivative of insulin or an insulin analogue, or physiologically acceptable salt of said derivative is administered intravenously.

Claim 40 (Previously Presented) The method of claim 32, wherein said insulin analogue is administered intravenously.

Claim 41 (Previously Presented) The method of claim 33, wherein said Asp^{B28} human insulin is administered intravenously.

Claim 42 (Previously Presented) The method of claim 34, wherein said Lys^{B28}, Pro^{B29} human insulin is administered intravenously.

Claim 43 (Previously Presented) The method of claim 35, wherein said active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered intravenously.

Claim 44 (Previously Presented) The method of claim 36, wherein said des-Thr^{B30} human

Express Mail Label No. EV 450788388 US
Attorney Docket No. 6296.204-US
Serial No. 09/853,193; Filed: May 11, 2001

insulin γ Lys^{B29} tetradecanoyl is administered intravenously.

Claim 45 (Previously Presented) The method of claim 37, wherein said insulin is administered intravenously.

Claim 46 (Previously Presented) The method of claim 38, wherein said human insulin is administered intravenously.

Claim 47 (Previously Presented) The method of claim 4, wherein an insulin analogue is administered to said CIPNP patient.

Claim 48 (Previously Presented) The method of claim 47, wherein said insulin analogue is Asp^{B28} human insulin.

Claim 49 (Previously Presented) The method of claim 47, wherein said insulin analogue is Lys^{B28}, Pro^{B29} human insulin.

Claim 50 (Previously Presented) The method of claim 4, wherein an active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered to said CIPNP patient.

Claim 51 (Previously Presented) The method of claim 50, wherein said active derivative of an insulin analogue is des-Thr^{B30} human insulin γ Lys^{B29} tetradecanoyl.

Claim 52 (Previously Presented) The method of claim 4, wherein insulin is administered to said CIPNP patient.

Claim 53 (Previously Presented) The method of claim 52, wherein said insulin is human insulin.

Express Mail Label No. EV 450788388 US
Attorney Docket No. 6296.204-US
Serial No. 09/853,193; Filed: May 11, 2001

Claim 54 (Previously Presented) The method of claim 4, wherein said insulin, insulin analogue, active derivative of insulin or an insulin analogue, or physiologically acceptable salt of said derivative is administered intravenously.

Claim 55 (Previously Presented) The method of claim 47, wherein said insulin analogue is administered intravenously.

Claim 56 (Previously Presented) The method of claim 48, wherein said Asp^{B28} human insulin is administered intravenously.

Claim 57 (Previously Presented) The method of claim 49, wherein said Lys^{B28}, Pro^{B29} human insulin is administered intravenously.

Claim 58 (Previously Presented) The method of claim 50, wherein said active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered intravenously.

Claim 59 (Previously Presented) The method of claim 51, wherein said des-Thr^{B30} human insulin γ Lys^{B29} tetradecanoyl is administered intravenously.

Claim 60 (Previously Presented) The method of claim 52, wherein said insulin is administered intravenously.

Claim 61 (Previously Presented) The method of claim 53, wherein said human insulin is administered intravenously.

Claim 62 (Previously Presented) The method of claim 40, wherein the patient is a human.

Claim 63 (Previously Presented) The method of claim 62, wherein the patient is non-diabetic.

Claim 64 (Previously Presented) The method of claim 41, wherein the patient is a human.

Claim 65 (Previously Presented) The method of claim 64, wherein the patient is non-diabetic.

Claim 66 (Previously Presented) The method of claim 42, wherein the patient is a human.

Claim 67 (Previously Presented) The method of claim 66, wherein the patient is non-diabetic.

Claim 68 (Previously Presented) The method of claim 43, wherein the patient is a human.

Claim 69 (Previously Presented) The method of claim 68, wherein the patient is non-diabetic.

Claim 70 (Previously Presented) The method of claim 44, wherein the patient is a human.

Claim 71 (Previously Presented) The method of claim 70, wherein the patient is non-diabetic.

Claim 72 (Previously Presented) The method of claim 46, wherein the patient is a human.

Claim 73 (Previously Presented) The method of claim 72, wherein the patient is non-diabetic.

Claim 74 (Previously Presented) The method of claim 55, wherein the patient is a human.

Claim 75 (Previously Presented) The method of claim 74, wherein the patient is non-diabetic.

Claim 76 (Previously Presented) The method of claim 56, wherein the patient is a human.

Claim 77 (Previously Presented) The method of claim 76, wherein the patient is non-diabetic.

Express Mail Label No. EV 450788388 US
Attorney Docket No. 6296.204-US
Serial No. 09/853,193; Filed: May 11, 2001

Claim 78 (Previously Presented) The method of claim 57, wherein the patient is a human.

Claim 79 (Previously Presented) The method of claim 78, wherein the patient is non-diabetic.

Claim 80 (Previously Presented) The method of claim 58, wherein the patient is a human.

Claim 81 (Previously Presented) The method of claim 80, wherein the patient is non-diabetic.

Claim 82 (Previously Presented) The method of claim 59, wherein the patient is a human.

Claim 83 (Previously Presented) The method of claim 82, wherein the patient is non-diabetic.

Claim 84 (Previously Presented) The method of claim 61, wherein the patient is a human.

Claim 85 (Previously Presented) The method of claim 84, wherein the patient is non-diabetic.